Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox 4 protein (DUX4) is a transcription factor that plays a crucial role in early embryonic development. Its aberrant expression in muscle tissue is the primary cause of facioscapulohumeral muscular dystrophy (FSHD). DUX4 regulates gene expression through its two homeodomains and controls genes involved in muscle cell differentiation and function. In FSHD, DUX4's toxic gain-of-function disrupts normal muscle biology, making it a key therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double Homeobox 4 Protein (DUX4).